USA Rare Earth, Inc. (USAR)

Theseus Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	40.57	-15.74	-7.42	-23.84
Depreciation & Amortization	0.29	0.39	0.72	0.67
Loss (Gain) From Sale of Assets	-	0.04	-	-
Loss (Gain) From Sale of Investments	0.41	0.41	-	1.35
Stock-Based Compensation	2.67	1.74	1.37	1.62
Other Operating Activities	-60.18	0.03	-16.97	-0.09
Change in Accounts Payable	-1.32	1.09	-2	0.32
Change in Unearned Revenue	-	-	4.83	3.37
Change in Other Net Operating Assets	-1.52	-0.95	-2.46	1.8
Operating Cash Flow	-19.09	-12.99	-21.93	-14.8
Capital Expenditures	-5.32	-3.29	-5.96	-15.15
Investing Cash Flow	-5.32	-3.29	-5.96	-15.15
Long-Term Debt Issued	-	-	1	-
Net Debt Issued (Repaid)	-	-	1	-
Issuance of Common Stock	-	-	-	20.24
Other Financing Activities	-8.54	-5.66	-0.19	2.02
Financing Cash Flow	40.21	19.84	14.11	22.26
Miscellaneous Cash Flow Adjustments	-	-	-0.36	-
Net Cash Flow	15.81	3.56	-14.14	-7.7
Free Cash Flow	-24.4	-16.28	-27.88	-29.95
Free Cash Flow Per Share	-0.10	-0.35	-0.63	-0.14
Levered Free Cash Flow	-	-15.2	-24.72	-
Unlevered Free Cash Flow	-	-15	-24.67	-
Change in Net Working Capital	-	4.11	5.31	-

Updated Mar 19, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.